IMCR:NASDAQImmunocore Holdings plc Analysis

Immunocore (IMCR) is trading at $31.30, well above its DCF‑derived fair value of $25.54, implying a price premium of over 100% (upside/downside ≈ 104%). The stock sits below its 20‑day SMA ($30.61) but under the 50‑day ($31.76) and 200‑day ($33.77) averages, signaling a short‑term pull‑back within a longer‑term bearish bias. Technicals are mixed: the RSI is near neutral at 50.4, the MACD histogram is positive (0.26) with a bullish signal line crossover, and volume is trending higher, yet the price remains trapped between support at $28.90 and resistance at $32.83. Recent earnings missed expectations (reported EPS = ‑0.62 vs. consensus ‑0.28) and operating cash flow remains negative, underscoring near‑term earnings pressure.
On the upside, revenue jumped 29% year‑over‑year, driven by strong KIMMTRAK sales, and the company will present five‑year overall survival data for KIMMTRAK at the March 2026 AACR meeting, a catalyst that could re‑price expectations. The pipeline includes multiple Phase 3 oncology programs and early‑stage infectious‑disease candidates, offering long‑term growth potential despite current profitability challenges.